Study guide

10.7 Acute Kidney Injury and Contrast-Associated Nephropathy

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

10.7 Acute Kidney Injury and Contrast-Associated Nephropathy

Key Takeaways Explain This Topic AI

KDIGO defines AKI as a creatinine rise of 0.3 mg/dL or more within 48 hours, a rise to 1.5 times baseline within 7 days, or urine output under 0.5 mL/kg/h for 6 hours; stage 3 is 3 times baseline, a creatinine of 4.0 mg/dL or more, or initiation of renal replacement therapy.

FEUrea, not FENa, is the discriminating test in the diuretic-treated cardiac patient: FEUrea under 35% indicates prerenal physiology, above 50-65% indicates tubular injury.

Isotonic crystalloid before and after contrast is the only well-supported prevention of contrast-associated AKI; N-acetylcysteine and sodium bicarbonate are NOT supported by the PRESERVE trial and are no longer recommended.

Metformin does not cause contrast nephropathy — it is held for 48 hours after contrast when eGFR is under 30 mL/min/1.73 m2 or AKI develops, because impaired clearance risks lactic acidosis.

In cardiorenal AKI, a central venous pressure above 12-15 mmHg predicts renal dysfunction more strongly than a low cardiac index, so venous decongestion is often the therapeutic priority over raising forward flow.

Last updated: August 2026

Why AKI Is a Cardiac Outcome Measure

Test-plan item II.E.1 is examined from the angle that matters clinically: acute kidney injury (AKI) in a cardiac patient is a marker of hemodynamic failure and a driver of mortality, not an incidental lab abnormality. A creatinine rise of only 0.3 mg/dL after admission for decompensated heart failure roughly doubles in-hospital mortality. AKI forces reduction or withdrawal of the guideline-directed medical therapy that keeps the patient alive, restricts contrast for the angiogram they need, contraindicates the anticoagulant they were on, and lengthens stay. The nurse who reports a falling hourly urine output at hour 6 rather than a rising creatinine at hour 48 is the one who changes the trajectory.

KDIGO Definition and Staging

AKI is present when any one of these is met: a serum creatinine rise of 0.3 mg/dL or more within 48 hours ; a rise to 1.5 times baseline known or presumed to have occurred within the prior 7 days ; or urine output under 0.5 mL/kg/h for 6 hours .

  • KDIGO stage Serum creatinine criterion Urine output criterion
  • 1 1.5–1.9 times baseline, or an increase of 0.3 mg/dL or more Under 0.5 mL/kg/h for 6–12 hours
  • 2 2.0–2.9 times baseline Under 0.5 mL/kg/h for 12 hours or more

3 3.0 times baseline or more , or a rise to 4.0 mg/dL or more , or initiation of renal replacement therapy (RRT) Under 0.3 mL/kg/h for 24 hours or more , or anuria for 12 hours or more

Two testable subtleties. First, the patient is staged by whichever criterion is worse — a patient making 0.2 mL/kg/h for 24 hours is stage 3 even if the creatinine has barely moved, because creatinine lags injury by 24–48 hours. Second, in a cachectic patient with low muscle mass or in a patient who has received large-volume resuscitation, creatinine is diluted and falsely reassuring ; urine output and trajectory are more honest.

The Differential, Written in Cardiac Terms

Prerenal (functional) — reduced effective renal perfusion, tubules intact:

Low cardiac output from cardiogenic shock, severe HFrEF, or a post-cardiotomy low-output state.

Venous congestion — the most under-recognized cause. A CVP above 12–15 mmHg raises renal interstitial and venous pressure, collapsing the transrenal perfusion gradient. In decompensated heart failure, elevated CVP predicts AKI more strongly than a low cardiac index. This is why aggressive decongestion often improves creatinine.

Overdiuresis, hypotension, vasodilator or sedation-related hypotension, RAAS inhibitors and NSAIDs impairing autoregulation.

Intrinsic — tubular, interstitial, glomerular or vascular injury:

Acute tubular necrosis (ATN) from prolonged ischemia or sepsis.

Iodinated contrast after catheterization or CT angiography.

Atheroembolic (cholesterol embolization) disease after aortic instrumentation — a subacute stepwise creatinine rise days to weeks after catheterization, with livedo reticularis, blue toes, eosinophilia and low complement. It does not respond to hydration.

Pigment nephropathy from hemolysis — the signature of mechanical circulatory support (Impella, VA-ECMO, LVAD pump thrombosis) with rising LDH and plasma free hemoglobin, and from rhabdomyolysis after prolonged down time or limb ischemia.

Cardiac-surgery-associated AKI (CSA-AKI) , affecting roughly 20–30% of bypass patients, driven by cardiopulmonary bypass duration, non-pulsatile low perfusion pressure, hemolysis and inflammation.

Interstitial nephritis from antibiotics, proton pump inhibitors or diuretics; endocarditis-related glomerulonephritis .

Postrenal — obstruction: clot retention after anticoagulated hematuria, a kinked or clogged urinary catheter (always flush or exchange the catheter before declaring anuria), prostatic obstruction, and abdominal compartment syndrome with a bladder pressure above 20 mmHg plus new organ dysfunction — a genuine risk in massively resuscitated post-arrest and post-surgical patients.

Discriminating Prerenal From Intrinsic at the Bedside

Test Prerenal Intrinsic (ATN) Note

FENa = (urine Na x plasma Cr) / (plasma Na x urine Cr) x 100 Under 1% Over 2% Invalid on diuretics, in CKD, and in contrast nephropathy (which is classically low-FENa despite tubular injury)

FEUrea = (urine urea x plasma Cr) / (BUN x urine Cr) x 100 Under 35% Over 50–65% Preferred whenever the patient is on a loop or thiazide diuretic — which is nearly every cardiac patient

  • Urine sodium Under 20 mEq/L Over 40 mEq/L Same diuretic caveat
  • BUN-to-creatinine ratio Over 20:1 10–15:1 Falsely raised by GI bleeding, steroids, high protein load

Urine microscopy Bland, hyaline casts Muddy brown granular casts , renal tubular epithelial cells WBC casts indicate interstitial nephritis; RBC casts indicate glomerulonephritis

Urine specific gravity/osmolality High (over 1.020; over 500 mOsm/kg) Isosthenuric (about 1.010; under 350 mOsm/kg)

Adjuncts: bladder pressure for compartment syndrome, point-of-care renal and IVC ultrasound for hydronephrosis and volume assessment (with venous excess ultrasound patterns describing hepatic, portal and intrarenal vein Doppler as congestion markers), and damage biomarkers such as urinary TIMP-2 x IGFBP7, NGAL and cystatin C that flag tubular stress before creatinine rises.